Injection of botulinum toxin before pneumatic dilatation in achalasia treatment: a randomized‐controlled trial

Summary Background Pneumatic dilatation is the first line therapy in achalasia, but half of patients relapse within 5 years of therapy and require further dilatations. Aim To assess whether botulinum toxin injection before pneumatic dilatation is superior to pneumatic dilatation alone in achalasia p...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Alimentary Pharmacology and Therapeutics 2006-09, Vol.24 (6), p.983-989
Hauptverfasser: MIKAELI, J., BISHEHSARI, F., MONTAZERI, G., MAHDAVINIA, M., YAGHOOBI, M., DARVISH‐MOGHADAM, S., FARROKHI, F., SHIRANI, S., ESTAKHRI, A., MALEKZADEH, R.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Summary Background Pneumatic dilatation is the first line therapy in achalasia, but half of patients relapse within 5 years of therapy and require further dilatations. Aim To assess whether botulinum toxin injection before pneumatic dilatation is superior to pneumatic dilatation alone in achalasia patients. Methods Newly diagnosed achalasia patients were randomly assigned to receive botulinum toxin 1 month before pneumatic dilatation (botulinum toxin‐pneumatic dilatation group: 27 patients with median age of 38) or to undergo pneumatic dilatation alone (pneumatic dilatation group: 27 patients with median age of 30). Response to therapy was assessed by clinical and objective methods at various intervals. Results One‐year remission rate of patients in botulinum toxin‐pneumatic dilatation group was 77% compared with 62% in pneumatic dilatation group (P = 0.1). In pneumatic dilatation group, the oesophageal barium volume significantly (P 
ISSN:0269-2813
0953-0673
1365-2036
0269-2813
DOI:10.1111/j.1365-2036.2006.03083.x